{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:44:38Z","timestamp":1772120678815,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T00:00:00Z","timestamp":1402876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clinthera.2014.06.008","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T16:31:44Z","timestamp":1404837104000},"page":"1130-1146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01012037","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01243424","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01897532","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael","family":"Lehrke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Seck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"von Eynatten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odd Erik","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.06.008_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-012-2534-0","article-title":"Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"55","author":"Inzucchi","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2014.06.008_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.diabet.2011.11.001","article-title":"DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials","volume":"38","author":"Scheen","year":"2012","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1517\/13543780903463862","article-title":"Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes","volume":"19","author":"Deacon","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2014.06.008_bib4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1463-1326.2009.01046.x","article-title":"Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients","volume":"11","author":"Heise","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"Thomas","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2014.06.008_bib6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/0091270008323753","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers","volume":"48","author":"Huttner","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.008_bib7","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1463-1326.2011.01386.x","article-title":"The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus","volume":"13","author":"Forst","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/dmd.109.031476","article-title":"The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans","volume":"38","author":"Blech","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.008_bib9","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Tradjenta\u2122 (linagliptin) tablets US Prescribing Information. 2011."},{"key":"10.1016\/j.clinthera.2014.06.008_bib10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1463-1326.2010.01212.x","article-title":"Pharmacokinetics of dipeptidylpeptidase-4 inhibitors","volume":"12","author":"Scheen","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1463-1326.2011.01458.x","article-title":"Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*)","volume":"13","author":"Graefe-Mody","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/qjmed\/hcm081","article-title":"Gliptins: a new class of oral hypoglycaemic agent","volume":"100","author":"Chahal","year":"2007","journal-title":"QJM"},{"key":"10.1016\/j.clinthera.2014.06.008_bib13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","article-title":"Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects","volume":"44","author":"Deacon","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes","volume":"25","author":"Ahr\u00e9n","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.06.008_bib15","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.06.008_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1463-1326.2010.01350.x","article-title":"Effect of linagliptin monotherapy on glycaemic control and markers of \u03b2-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial","volume":"13","author":"Del Prato","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1463-1326.2011.01391.x","article-title":"Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study","volume":"13","author":"Gomis","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib18","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/j.1464-5491.2011.03387.x","article-title":"Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study","volume":"28","author":"Owens","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2014.06.008_bib19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1463-1326.2010.01326.x","article-title":"Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"13","author":"Taskinen","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(12)60691-6","article-title":"2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial","volume":"380","author":"Gallwitz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.06.008_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/ijcp.12101","article-title":"Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c < 7% with no hypoglycaemia and no weight gain over 2 years","volume":"67","author":"Gallwitz","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.06.008_bib22","first-page":"A255","article-title":"Efficacy and Safety of Linagliptin as Add-On Therapy to Basal Insulin in Patients With Type 2 Diabetes","volume":"61","author":"Yki-Jarvinen","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib23","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1463-1326.2012.01565.x","article-title":"Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus","volume":"14","author":"Schernthaner","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib24","first-page":"S32","article-title":"Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate","volume":"53","author":"Barnett","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2014.06.008_bib25","first-page":"A190","article-title":"Linagliptin monotherapy improves glycaemic control in Japanese patients with T2DM over 12 weeks","volume":"59","author":"Kawamori","year":"2010","journal-title":"Diabetes"},{"issue":"Suppl.1","key":"10.1016\/j.clinthera.2014.06.008_bib26","first-page":"821","article-title":"Safety and efficacy of linagliptin add-on therapy to sulphonylurea in inadequately controlled type 2 diabetes","volume":"53","author":"Lewin","year":"2010","journal-title":"Diabetologia"},{"issue":"Suppl.1","key":"10.1016\/j.clinthera.2014.06.008_bib27","first-page":"A77","article-title":"Combination of linagliptin and metformin improves glycemic control in type 2 diabetes: a randomized trial with an open-label arm in patients with poor glycemic control","volume":"53","author":"Haak","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2014.06.008_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s13300-012-0010-y","article-title":"Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus","volume":"3","author":"Rauch","year":"2012","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2014.06.008_bib29","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","article-title":"Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes","volume":"27","author":"Forst","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.clinthera.2014.06.008_bib30","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1463-1326.2012.01586.x","article-title":"The effect of linagliptin on glycaemic control and tolerability in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Singh-Franco","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib31","first-page":"S9","article-title":"Long-term safety and efficacy of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes: a 52-week randomised, placebo-controlled trial","volume":"55","author":"Yki-J\u00e4rvinen","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2014.06.008_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.06.008_bib33","first-page":"A283","article-title":"Linagliptin improved glycemic control without weight gain or hypoglycemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone","volume":"62","author":"Bajaj","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib34","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1185\/03007995.2012.714360","article-title":"Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, placebo-controlled trial","volume":"28","author":"Ross","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.06.008_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(13)61500-7","article-title":"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Barnett","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.06.008_bib36","first-page":"A281","article-title":"Linagliptin vs placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment","volume":"62","author":"Laakso","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib37","first-page":"A302","article-title":"Efficacy and safety of linagliptin monotherapy in Asian patients with inadequately controlled type 2 diabetes mellitus: a 24-week, randomized, Phase III clinical trial","volume":"62","author":"Chen","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib38","first-page":"A307","article-title":"Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin: a 24-week, randomized, Phase III clinical trial","volume":"62","author":"Wang","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib39","unstructured":"Thrasher J, Ahmed A, Daniels K, et al. Randomized, placebo-controlled, double-blind, 24-week study of linagliptin 5mg\/day in black\/African American patients with type 2 diabetes. Abstract 206. https:\/\/www.aace.com\/files\/abstracts-2012.pdf. Accessed February 12, 2014."},{"key":"10.1016\/j.clinthera.2014.06.008_bib40","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1463-1326.2012.01590.x","article-title":"Initial combination of linagliptin and metformin improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"14","author":"Haak","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib41","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/dom.12110","article-title":"Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes","volume":"15","author":"Inagaki","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib42","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1210\/jc.2008-2152","article-title":"Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes","volume":"94","author":"Ahr\u00e9n","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2014.06.008_bib43","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib44","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.2337\/db11-0979","article-title":"Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans","volume":"60","author":"Christensen","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2014.06.008_bib45","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2337\/db06-0738","article-title":"Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1","volume":"56","author":"de Heer","year":"2007","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2014.06.008_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1463-1326.2008.00883.x","article-title":"Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France","volume":"10","author":"Vexiau","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2014.06.008_bib47","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.2337\/dc11-s231","article-title":"Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability","volume":"34","author":"Garber","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2014.06.008_bib48","unstructured":"Bristol-Myers Squibb Company. ONGLYZA\u2122 (saxagliptin) tablets. US Prescribing Information. 2011."},{"key":"10.1016\/j.clinthera.2014.06.008_bib49","unstructured":"Merck Sharp & Dohme Corp. JANUVIA\u00ae (sitagliptin) tablets. US Prescribing Information. 2011."},{"key":"10.1016\/j.clinthera.2014.06.008_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","article-title":"Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies","volume":"141","author":"Elashoff","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2014.06.008_bib51","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2014.06.008_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1475-2840-11-3","article-title":"Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme","volume":"11","author":"Johansen","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2014.06.008_bib53","unstructured":"European Medicines Agency. Assessment Report: Trajenta. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/002110\/WC500135743.pdf. Accessed 13 March 2013."},{"key":"10.1016\/j.clinthera.2014.06.008_bib54","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.06.008_bib55","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.06.008_bib56","unstructured":"White W. Results from EXAMINE. Oral presentation at EASD 2013. http:\/\/www.easdvirtualmeeting.org\/resources\/7109. Accessed March 13, 2014."},{"key":"10.1016\/j.clinthera.2014.06.008_bib57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1479164112475102","article-title":"Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial","volume":"10","author":"Rosenstock","year":"2013","journal-title":"Diab Vasc Dis Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:24Z","timestamp":1758962964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814003713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0149291814003713"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.008","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726349895.793518337","asserted-by":"object"}]},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}